Insight

Reference

·

Primary source

Pharma imports share

~70%

As ofFY2024·Sources2·Primary

Imports dominate Thai pharma — originator drugs, patented specialties from MNC pharma. Local manufacturing concentrated in generics, essential drugs.

Download CSV ↓Compare plans →

Figure in context

Imports dominate Thai pharma — originator drugs, patented specialties from MNC pharma. Local manufacturing concentrated in generics, essential drugs.

Imports dominate Thai pharma — originator drugs, patented specialties from MNC pharma. Local manufacturing concentrated in generics, essential drugs.

Time scope

FY2024

Source basis

Primary source

Interpretation notes

What this tells you

Imports dominate Thai pharma — originator drugs, patented specialties from MNC pharma. Local manufacturing concentrated in generics, essential drugs.

What not to do with it

Structural trade deficit driver; policy tension with BOI, DIP on local manufacturing, patent policy.

Related figures

Adjacent numbers that add context without drowning the value.

FY2024
~THB 250B

Thai pharmaceutical market size

PReMA, TPMA, FDA Thailand, IQVIA

FY2024
~10-15%

GPO (Government Pharma Organisation) share

GPO annual report, NHSO

FY2024
~THB 60B

UCS (Universal Coverage Scheme) drug expenditure

NHSO budget, MOPH

FY2024
~THB 40B combined

Listed pharma distributor revenue (Mega, DCC)

MEGA, DCC 56-1 FY2024

Report context

Thailand Pharmaceuticals Market Intelligence

Thailand's pharmaceuticals market reached approximately THB 280B in FY2024, split roughly 75% imported (originators, generics) and 25% domestic (GPO state, listed, private generics). Government Pharmaceutical Organisation is the state anchor for essential medicines, ARV, biosimilar manufacturing. Mega Lifesciences (SET: MEGA) is the largest Thai-listed pharma (~THB 16B revenue). Multinational originator subsidiaries (GSK, Pfizer, Novartis, Roche) lead originator, specialty supply. UCS, SSS, CSMBS multi-payer framework, NLEM reimbursement drive price-competition dynamics.

Open report →

Atlas actors in this figure's reports

Profiles covered in the report that cite this number.

Government Pharmaceutical Organisation (GPO)

Thai state pharmaceutical manufacturer; generics, HIV ARV, biosimilar, Strategic Stockpile; FY2024 revenue ~THB 16B.

GSK Thailand

UK-parent MNC originator Thai subsidiary; respiratory, vaccines, HIV, oncology; ~8% Thai market value share.

Mega Lifesciences

Largest Thai-listed pharma by revenue; emerging-market distribution franchise; FY2024 revenue ~THB 16B.

Novartis Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, cardiovascular, biosimilar; ~6% Thai market value share.

Pfizer Thailand

US-parent MNC originator Thai subsidiary; oncology, primary care, vaccines; ~7% Thai market value share.

Roche Thailand

Swiss-parent MNC specialty Thai subsidiary; oncology, biologics, diagnostics; ~5% Thai market value share.

Pharma imports share · Insight